CytomX Therapeutics Debt to Equity Ratio 2014-2022 | CTMX
Current and historical debt to equity ratio values for CytomX Therapeutics (CTMX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. CytomX Therapeutics debt/equity for the three months ending September 30, 2022 was 0.00.
| CytomX Therapeutics Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-09-30 |
$0.20B |
$0.03B |
6.95 |
| 2022-06-30 |
$0.21B |
$0.05B |
4.34 |
| 2022-03-31 |
$0.23B |
$0.07B |
3.35 |
| 2021-12-31 |
$0.25B |
$0.09B |
2.80 |
| 2021-09-30 |
$0.26B |
$0.11B |
2.32 |
| 2021-06-30 |
$0.27B |
$0.13B |
2.07 |
| 2021-03-31 |
$0.29B |
$0.15B |
1.97 |
| 2020-12-31 |
$0.31B |
$0.05B |
6.20 |
| 2020-09-30 |
$0.33B |
$0.05B |
6.81 |
| 2020-06-30 |
$0.34B |
$0.06B |
5.84 |
| 2020-03-31 |
$0.37B |
$0.07B |
5.26 |
| 2019-12-31 |
$0.29B |
$0.05B |
5.68 |
| 2019-09-30 |
$0.29B |
$0.08B |
3.54 |
| 2019-06-30 |
$0.30B |
$0.10B |
2.99 |
| 2019-03-31 |
$0.32B |
$0.12B |
2.63 |
| 2018-12-31 |
$0.33B |
$0.13B |
2.49 |
| 2018-09-30 |
$0.33B |
$0.16B |
2.06 |
| 2018-06-30 |
$0.34B |
$0.04B |
8.16 |
| 2018-03-31 |
$0.33B |
$0.05B |
6.58 |
| 2017-12-31 |
$0.33B |
$0.07B |
4.69 |
| 2017-09-30 |
$0.34B |
$0.05B |
7.51 |
| 2017-06-30 |
$0.30B |
$0.05B |
5.74 |
| 2017-03-31 |
$0.10B |
$0.07B |
1.41 |
| 2016-12-31 |
$0.12B |
$0.08B |
1.54 |
| 2016-09-30 |
$0.10B |
$0.09B |
1.16 |
| 2016-06-30 |
$0.11B |
$0.10B |
1.04 |
| 2016-03-31 |
$0.08B |
$0.11B |
0.70 |
| 2015-12-31 |
$0.07B |
$0.13B |
0.56 |
| 2015-09-30 |
$0.07B |
$0.05B |
1.35 |
| 2015-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2015-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2014-12-31 |
$0.00B |
|
0.00 |
| 2014-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2013-12-31 |
$0.01B |
$0.00B |
31.95 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.115B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
